Avid Bioservices will make IOV-3001, Iovance Therapeutics’ candidate interleukin-2 receptor agonist intended for the treatment of cancer. Avid will commence analytical activities, upstream and downstream process development, and pilot-scale non-GMP manufacturing for IOV-3001. The firm will also work with Aragen Biosciences, which is carrying out cell line development activities. The next stage will see Avid manufacture the drug at its Myford facility in Tustin, California. News of the contract comes just a month after Avid said it planned to increase…